By Colin Kellaher

Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit Monday said the U.S. Food and Drug Administration approved the blood thinner Xarelto for the prevention of venous thromboembolism, or blood clots, in acutely ill medical patients.

Janssen said the approval for Xarelto, which it jointly developed with Germany's Bayer AG (BAYN.XE), covers hospitalized acutely ill medical patients at risk for thromboembolic complications who aren't at high risk of bleeding.

Janssen said the FDA has granted Xarelto eight indications, including six specifically for the treatment, prevention and reduction in the risk of recurrence of venous thromboembolism across a range of patient populations.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

October 14, 2019 09:37 ET (13:37 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024 Plus de graphiques de la Bourse Johnson and Johnson
Johnson and Johnson (NYSE:JNJ)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024 Plus de graphiques de la Bourse Johnson and Johnson